1. Home
  2. BBLG vs PRFX Comparison

BBLG vs PRFX Comparison

Compare BBLG & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBLG

Bone Biologics Corp

HOLD

Current Price

$0.94

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$1.07

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBLG
PRFX
Founded
2004
2007
Country
United States
Israel
Employees
2
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BBLG
PRFX
Price
$0.94
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.0K
124.3K
Earning Date
05-13-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$0.58
52 Week High
$4.13
$5.39

Technical Indicators

Market Signals
Indicator
BBLG
PRFX
Relative Strength Index (RSI) 44.04 43.48
Support Level N/A $0.83
Resistance Level $1.38 $1.25
Average True Range (ATR) 0.08 0.10
MACD 0.00 0.02
Stochastic Oscillator 60.00 40.85

Price Performance

Historical Comparison
BBLG
PRFX

About BBLG Bone Biologics Corp

Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: